La vendita allo scoperto per Biomarin Pharmaceutical dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Biomarin Pharmaceutical. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Biomarin Pharmaceutical (NASDAQ:BMRN) Azioni, Report sulle vendite allo scoperto

Biomarin Pharmaceutical

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical Inc

BIOMARIN PHARMACEUTICAL ORD

In October, CAMP4 Therapeutics Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAMP#NASDAQ">CAMP</a>) priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million <a href="https://www.benzinga.com/pressreleases/24/10/g41283554/camp4-announces-pricing-of-initial-public-offering" target="_blank" rel="noreferrer noopener">in gross proceeds</a>.
Camp4 is an RNA therapeutics company focused on developing therapies for rare diseases.
CAMP4 Therapeutics <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-cmp-cps-001-a-potential-first-in-class-therapeutic-for-urea-cycle-disorders/" rel="noreferrer noopener">dosed</a> the first participant in its Phase 1 study of CMP-CPS-001 for urea cycle disorders (UCDs) in March.
CMP-CPS-001 has secured FDA <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-orphan-drug-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Orphan</a> Drug and Rare Pediatric <a target="_blank" href="https://www.camp4tx.com/camp4-therapeutics-secures-rare-pediatric-disease-designation-for-cmp-cps-001-for-the-treatment-of-urea-cycle-disorders/" rel="noreferrer noopener">Disease </a>Designations for urea cycle disorders.
Last month, the company announced a <a target="_blank" href="https://www.camp4tx.com/camp4-enters-strategic-research-collaboration-to-advance-novel-regulatory-rna-targeting-medicines-for-rare-genetic-conditions/" rel="noreferrer noopener">new</a> research collaboration with BioMarin Pharmaceutical Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) to advance novel therapeutics that increase protein levels by targeting regulatory RNA (regRNA) sequences, key elements controlling gene expression.
Under the terms of the agreement, BioMarin has the right to select two targets identified by CAMP4's RAP Platform to advance into clinical development.
William Blair initiated coverage on CAMP4 Therapeutics, noting that Camp4&#8217;s shares trade at a significantly lower market cap than other early-stage genetic medicine companies, even though it has the innovative RAP platform. This unique platform offers a novel approach to enhancing target gene expression for rare diseases.
Piper Sandler initiated coverage on CAMP4 Therapeutics, noting that regRNAs could be the next big RNA modality with advantages over protein replacement or gene therapy.
The Piper analyst writes that any increase in ureagenesis rate test (URT) would be a signal of on-target CMP-CPS-001 ammonia lowering and provide proof-of-concept for urea cycle disorders patients.
The analyst expects CAMP4 to conduct registrational Phase 2 studies in urea cycle disorders patients and could gain FDA approval in 2029 with peak CMP-CPS-001 revenues of $1.0 billion by 2036.
Piper has initiated coverage of CAMP4 with an Overweight rating and a <a target="_blank" href="https://www.benzinga.com/quote/CAMP/analyst-ratings" rel="noreferrer noopener">price target of $18</a>.
Price Action: CAMP stock is up 13.5% at $9.33 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/11/41753070/alibaba-brings-singles-day-shopping-extravaganza-to-us-with-big-discounts" target="_blank" rel="noreferrer noopener">Alibaba Brings Singles&#8217; Day Shopping Extravaganza to US with Big Discounts</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Analyst Color

Biotech

News

Health Care

Initiation

Analyst Ratings

Movers

Trading Ideas

General

BMRN

CAMP

CAMP4 Analyst Highlights Rare Disease Platform Potential

On Tuesday, Biomarin Pharmaceutical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) <a href="https://www.benzinga.com/earnings">reported third-quarter</a> adjusted EPS of 91 cents, almost double the 46 cents reported a year ago, beating the consensus of 52 cents.
The company reported sales of $745.74 million, beating the consensus of $700.14 million. Sales increased 28%, driven by strong VOXZOGO contributions from new <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/n41610287/biomarin-announces-28-yy-total-revenue-growth-in-the-third-quarter-and-increase-in-full-year-2024-" rel="noreferrer noopener">patient starts in all regions</a>.
In the quarter, revenues from BioMarin&#8217;s Enzyme Therapies (Vimizim, Naglazyme, Aldurazyme, Brineura, and Palynziq) increased 27% year over year.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/09/41033938/biomarin-stands-firm-on-2027-revenue-target-amid-ascendis-competition-goldman-sachs" rel="noreferrer noopener">BioMarin Stands Firm on 2027 Revenue Target Amid Ascendis Competition, Goldman Sachs Analyst Remains Bullish</a>
Guidance: BioMarin reaffirmed its long-term guidance and outlook, targeting around $4 billion in revenues in 2027.
The company expects a 40% adjusted operating margin starting in 2026 and growing to the low-to mid-40% range over time.
William Blair has downgraded <a target="_blank" href="https://www.benzinga.com/quote/BMRN/analyst-ratings" rel="noreferrer noopener">BioMarin to a Market Perform</a>.
The analyst adds, &#8220;We believe the company&#8217;s current valuation adequately reflects revenue estimates for the company&#8217;s commercial portfolio, and we do not think its clinical pipeline will be a source of significant value creation in the near term.&#8221;
William Blair models 2024 and 2025 revenue of $2.8 billion and $3.1 billion, respectively.
Voxzogo sales increased 54% to $190 million in the third quarter. The analyst says Voxzogo remains the company&#8217;s key topline growth driver, but the threat of competition could erode its revenue growth and market share.
Last month, Ascendis Pharma A/S&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASND#NASDAQ">ASND</a>) released topline data from a trial in achondroplasia, showing its long-acting CNP, navepegritide, could potentially deliver similar efficacy as Voxzogo but with a more attractive once-weekly dosing.
Although Voxzogo&#8217;s label might expand, William Blair does not anticipate a significant increase in the total addressable patient population until 2030.
Despite BioMarin&#8217;s strong pipeline, the analyst does not consider data readouts from its early-stage programs over the next year as significant value drivers.
Only two programs are expected to contribute to BioMarin&#8217;s top line through label expansions by 2027: Palynziq for adolescent Phenylketonuria (PKU) patients and Voxzogo for Hypochondroplasia&nbsp;(HCH).
Analyst Reaction:
<ul>
<li>Baird maintains Biomarin and lowers the price target from $72 to $65.</li>
<li>UBS reaffirms the Buy rating, raising the price target from $104 to $106.</li>
<li>Evercore ISI maintains Biomarin with an Outperform rating, lowering the price target from $115 to $105.</li>
<li>RBC Capital reiterates Biomarin with a Sector Perform and price target of $80.</li>
</ul>
Price Action: BMRN stock is down 3.1% at $67.74 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/10/41629194/wingstop-q3-eps-misses-as-chicken-wing-costs-bite-strong-sales-growth-aggressive-expansion-plans-mo" target="_blank" rel="noreferrer noopener">Wingstop Q3: EPS Misses As Chicken Wing Costs Bite, Strong Sales Growth, Aggressive Expansion Plans &amp; More</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Earnings

Large Cap

Guidance

Downgrades

ASND

BioMarin's Pipeline Faces Skepticism As Analyst Questions Future Growth

Citigroup analyst David Lebovitz maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $93 to $81.

Price Target

Citigroup Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $81

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Hold and lowers the price target from $93 to $84.

Canaccord Genuity Maintains Hold on Biomarin Pharmaceutical, Lowers Price Target to $84

Cantor Fitzgerald analyst Olivia Brayer maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $110 to $90.

Cantor Fitzgerald Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $90

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Overweight and lowers the price target from $110 to $109.

JP Morgan Maintains Overweight on Biomarin Pharmaceutical, Lowers Price Target to $109

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and maintains $80 price target.

Reiteration

RBC Capital Reiterates Sector Perform on Biomarin Pharmaceutical, Maintains $80 Price Target

Evercore ISI Group analyst Cory Kasimov maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform and lowers the price target from $115 to $105.

Evercore ISI Group Maintains Outperform on Biomarin Pharmaceutical, Lowers Price Target to $105

Throughout the last three months, 29 analysts have evaluated Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>), offering a diverse set of opinions from bullish to bearish.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">12</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Biomarin Pharmaceutical and provided 12-month price targets. The average target is $99.79, accompanied by a high estimate of $122.00 and a low estimate of $65.00. This current average represents a 5.98% decrease from the previous average price target of $106.14. 
<img src="https://www.benzinga.com/files/images/story/2024/1730296968_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
The analysis of recent analyst actions sheds light on the perception of Biomarin Pharmaceutical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eliana Merle</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$106.00</td>
<td>$104.00</td>
</tr>
<tr>
<td>Joel Beatty</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$65.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Danielle Brill</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$79.00</td>
<td>-</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$80.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$86.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$78.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$90.00</td>
<td>$118.00</td>
</tr>
<tr>
<td>Mohit Bansal</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$90.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$85.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Geoff Meacham</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$87.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$90.00</td>
<td>$116.00</td>
</tr>
<tr>
<td>Whitney Ijem</td>
<td>Canaccord Genuity</td>
<td>Maintains</td>
<td>Hold</td>
<td>$93.00</td>
<td>$93.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$95.00</td>
<td>$86.00</td>
</tr>
<tr>
<td>Joon Lee</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$118.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$122.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Christopher Raymond</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$107.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>William Pickering</td>
<td>Bernstein</td>
<td>Raises</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Phil Nadeau</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$120.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>George Farmer</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$86.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Paul Matteis</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$112.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Cory Kasimov</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$115.00</td>
<td>$113.00</td>
</tr>
<tr>
<td>Olivia Brayer</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$110.00</td>
<td>$110.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Biomarin Pharmaceutical. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Biomarin Pharmaceutical compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Biomarin Pharmaceutical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Biomarin Pharmaceutical's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BMRN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Biomarin Pharmaceutical analyst ratings.</a>
<h2>All You Need to Know About Biomarin Pharmaceutical</h2>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Understanding the Numbers: Biomarin Pharmaceutical's Finances</h3>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
Revenue Growth: Biomarin Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.61%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 15.05%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.07%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.54%, the company showcases effective utilization of assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Basics of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

In-Depth Examination Of 29 Analyst Recommendations For Biomarin Pharmaceutical

UBS analyst Eliana Merle maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Buy and raises the price target from $104 to $106.

UBS Maintains Buy on Biomarin Pharmaceutical, Raises Price Target to $106

Baird analyst Joel Beatty maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Neutral and lowers the price target from $72 to $65.

Baird Maintains Neutral on Biomarin Pharmaceutical, Lowers Price Target to $65

William Blair analyst Tim Lugo downgrades Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) from Outperform to Market Perform.

William Blair Downgrades Biomarin Pharmaceutical to Market Perform

<ul>
<li>During the quarter, BioMarin reaffirmed long-term guidance and outlook previously provided at Investor Day on September 4, 2024, targeting:</li>
<li>&nbsp;
<ul>
<li>Approximately $4 billion in Total Revenues in 2027;</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>40% Non-GAAP Operating Margin(1) starting in 2026 and growing to the low- to mid-40% range over time;</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>More than $1.25 billion operating cash flow per year starting in 2027;</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Mid-teen compound annual growth rate (CAGR) for total revenues through 2034; and</li>
</ul>
</li>
<li>&nbsp;
<ul>
<li>Treatments for Skeletal Conditions to represent a greater than $5 billion revenue opportunity over time.</li>
</ul>
</li>
</ul>

BioMarin Reaffirms Long-Term Guidance And Outlook Previously Provided At Investor Day On September 4, 2024, Targeting ~$4B In Total Revenues In 2027; 40% Non-GAAP Operating Margin Starting In 2026 And Growing To The Low- To Mid-40% Range Over Time

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) reported quarterly earnings of $0.91 per share which beat the analyst consensus estimate of $0.52 by 75 percent. The company reported quarterly sales of $745.74 million which beat the analyst consensus estimate of $700.14 million by 6.51 percent. This is a 28.28 percent increase over sales of $581.33 million the same period last year.

Earnings Beats

Biomarin Pharmaceutical Q3 2024 Adj EPS $0.91 Beats $0.52 Estimate, Sales $745.74M Beat $700.14M Estimate

Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) is preparing to release its quarterly earnings on Tuesday, 2024-10-29. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Biomarin Pharmaceutical to report an earnings per share (EPS) of $0.52.
The announcement from Biomarin Pharmaceutical is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Earnings History Snapshot</h3>
During the last quarter, the company reported an EPS beat by $0.61, leading to a 7.95% increase in the share price on the subsequent day.
Here's a look at Biomarin Pharmaceutical's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.35</td>
<td>0.34</td>
<td>0.23</td>
<td>0.22</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.96</td>
<td>0.71</td>
<td>0.49</td>
<td>0.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>8.0%</td>
<td>-10.0%</td>
<td>1.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1730131317_0.png" alt="eps graph" />
<h3>Market Performance of Biomarin Pharmaceutical's Stock</h3>
Shares of Biomarin Pharmaceutical were trading at $69.73 as of October 25. Over the last 52-week period, shares are down 14.11%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Insights Shared by Analysts on Biomarin Pharmaceutical</h3>
For investors, grasping market sentiments and expectations in the industry is vital. This analysis explores the latest insights regarding Biomarin Pharmaceutical.
A total of 27 analyst ratings have been received for Biomarin Pharmaceutical, with the consensus rating being Outperform. The average one-year price target stands at $100.85, suggesting a potential 44.63% upside.
<h3>Comparing Ratings with Competitors</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Exact Sciences, Incyte and Sarepta Therapeutics, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Exact Sciences, with an average 1-year price target of $77.33, suggesting a potential 10.9% upside.</li>
<li>The consensus among analysts is an Neutral trajectory for Incyte, with an average 1-year price target of $69.67, indicating a potential 0.09% downside.</li>
<li>Sarepta Therapeutics received a Outperform consensus from analysts, with an average 1-year price target of $176.93, implying a potential 153.74% upside.</li>
</ul>
<h3>Summary of Peers Analysis</h3>
The peer analysis summary presents essential metrics for Exact Sciences, Incyte and Sarepta Therapeutics, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Biomarin Pharmaceutical</td>
<td>Outperform</td>
<td>19.61%</td>
<td>$581.57M</td>
<td>2.07%</td>
</tr>
<tr>
<td>Exact Sciences</td>
<td>Buy</td>
<td>12.41%</td>
<td>$509.46M</td>
<td>-0.50%</td>
</tr>
<tr>
<td>Incyte</td>
<td>Neutral</td>
<td>9.34%</td>
<td>$967.16M</td>
<td>-10.60%</td>
</tr>
<tr>
<td>Sarepta Therapeutics</td>
<td>Outperform</td>
<td>38.93%</td>
<td>$318.39M</td>
<td>0.63%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Biomarin Pharmaceutical ranks highest in Revenue Growth and Gross Profit among its peers. However, it has the lowest Return on Equity. Overall, Biomarin Pharmaceutical is positioned favorably compared to its peers in terms of financial performance.
<h3>Unveiling the Story Behind Biomarin Pharmaceutical</h3>
BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
<h3>Biomarin Pharmaceutical's Financial Performance</h3>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Biomarin Pharmaceutical's revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 19.61%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Biomarin Pharmaceutical's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 15.05% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Biomarin Pharmaceutical's ROE stands out, surpassing industry averages. With an impressive ROE of 2.07%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.54%, the company showcases effective utilization of assets.
Debt Management: With a below-average debt-to-equity ratio of 0.21, Biomarin Pharmaceutical adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/BMRN/earnings">To track all earnings releases for Biomarin Pharmaceutical visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Look Ahead: Biomarin Pharmaceutical's Earnings Forecast

Biomarin Pharmaceutical's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NYSE">BMRN</a>) short percent of float has fallen 12.26% since its last report. The company recently reported that it has 5.28 million shares sold short, which is 2.79% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.76 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Biomarin Pharmaceutical Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729013418_0_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Biomarin Pharmaceutical has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Biomarin Pharmaceutical's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Biomarin Pharmaceutical's peer group average for short interest as a percentage of float is 5.61%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

How Is The Market Feeling About Biomarin Pharmaceutical?

Raymond James analyst Danielle Brill reinstates Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Outperform and announces $79 price target.

Raymond James Reinstates Outperform on Biomarin Pharmaceutical, Announces $79 Price Target

The U.S. Department of Health and Human Services (HHS), through the Centers for Medicare &amp; Medicaid Services (CMS), has released a Request for Information (RFI) regarding a new initiative to lower prescription drug costs for Medicare recipients.
The Medicare $2 Drug List Model, developed under President Biden&#8217;s Executive Order 14087, seeks to offer certain generic drugs for a fixed copayment of no more than $2 per month.
This initiative targets commonly prescribed drugs for conditions like high cholesterol and high blood pressure.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/08/40534249/novo-nordisks-ozempic-might-be-among-2027-medicare-price-negotiation-targets" rel="noreferrer noopener">Novo Nordisk&#8217;s Ozempic Might Be Among 2027 Medicare Price Negotiation Targets</a>.
The Center for Medicare and Medicaid Innovation (Innovation Center) has designed the Medicare $2 Drug List Model to test whether simplifying access to affordable, clinically important generics will improve health outcomes, improve medication adherence, and boost overall satisfaction with the Medicare Part D program.
These drugs, which would not be subject to typical utilization management requirements, could be available at all participating pharmacies as early as January 2027.
The initial list of <a target="_blank" href="https://www.cms.gov/newsroom/press-releases/biden-harris-administration-takes-next-step-proposed-model-lower-prescription-drug-costs-people" rel="noreferrer noopener">drugs</a> for the $2 Drug List Model has been carefully developed through a rigorous process. It incorporates input from physicians, pharmacists, and health policy experts to ensure that the selected medications address common conditions for Medicare recipients.
The concept of a fixed-cost drug list is not new, with many retail pharmacies already offering generic medications at low, standardized prices.
However, the Medicare $2 Drug List Model will be tailored specifically to Medicare recipients.
Last week,&nbsp;the HHS released final guidance for the second &nbsp;Medicare Drug Price <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">Negotiation Program cycle</a>.
This initiative&nbsp;<a target="_blank" href="https://www.cms.gov/newsroom/press-releases/hhs-releases-final-guidance-second-cycle-historic-medicare-drug-price-negotiation-program" rel="noreferrer noopener">aims</a> to provide lower drug prices starting in 2026 and 2027.
The first round of negotiations focused on ten specific drugs. When the new prices take effect in 2026, Medicare recipients should save approximately $1.5 billion in <a target="_blank" href="https://www.benzinga.com/general/biotech/24/10/41166018/medicare-drug-price-negotiation-program-gets-final-guidance-for-second-cycle-1-5b-savings-expecte" rel="noreferrer noopener">out-of-pocket costs</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41256266/is-the-iphone-losing-its-buzz-among-teens-piper-sandler-finds-out" target="_blank" rel="noreferrer noopener">Is The iPhone Losing Its Buzz Among Teens? Piper Sandler Finds Out</a></li>
</ul>
Image via Shutterstock

Government

AMGN

GILD

REGN

VRTX

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients

Everybody loves finding a bargain or getting a good deal, and it&#39;s no different when it comes to stocks. One of the most popular technical indicators for helping investors find these is the Relative Strength Index (RSI).&nbsp;
Every stock has one. It works by considering a stock&#39;s recent performance over the past 14 trading days and spitting out a number ranging from 0 to 100. An RSI reading of more than 70 suggests extremely overbought conditions, while a reading below 30 suggests the opposite. The more extreme the reading, the more extreme the suggested condition of the stock.&nbsp;
With the benchmark S&amp;P 500 index back up around all-time highs since the Fed confirmed it was cutting rates, investor sentiment is clearly still bullish. This makes it all the more interesting when you then see a stock selling hard. Any indication that the selling might be verging on overdone or that the bears are running out of steam can mean a quick bounce is in store. With that in mind, here are three stocks with RSI readings that suggest they&#39;re extremely oversold.&nbsp;&nbsp;
<h2>Wall Street Sees Opportunity in Humana&#39;s Oversold Condition</h2>
Humana Inc., the for-profit health insurance company, has been selling off for over two years. Considering the gains the broader market has registered in this timeframe, the Louisville-based company&#39;s underperformance will be a bitter pill.&nbsp;
Its shares were down more than 50% in that timeframe and went back into trading at 2017 levels. Despite beating analyst expectations in its Q2 earnings report over the summer, things have only gotten worse, with yesterday&#39;s negative update on membership numbers the latest headwind to deal with.&nbsp;
At one point yesterday, Humana shares were trading more than 30% off where they closed last week, resulting in an RSI reading of just 15. This is the stock&#39;s lowest reading in 16 years, a fact that hasn&#39;t gone unnoticed by Wall Street. This isn&#39;t a company to be holding for the long run, but the strong buying action all the way into yesterday&#39;s close suggests there&#39;s a fast and hard bounce kicking off that can be capitalized on.&nbsp;
<h2>Elevance Health&#39;s Oversold RSI Suggests Significant Upside Potential</h2>
Though not quite as extreme as Humana&#39;s, Elevance Health, Inc (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/elv#NYSE">ELV</a>)&#39;s RSI reading of 26 does suggest the Indianapolis health insurer is extremely oversold.
Compared to Humana, however, there&#39;s a lot more to like about Elevance for the long term, not least the fact that the company was trading at all-time highs as recently as July.&nbsp;
While its stock has been softening since the first week of September, it gapped down at yesterday&#39;s open. This was almost certainly off the back of Humana&#39;s negative update, and already, it&#39;s being treated as an entry opportunity.&nbsp;
Elevance shares gained into Wednesday&#39;s close and were trading up in Thursday&#39;s pre-market session. Considering how low their RSI still is, however, there&#39;s clearly a ton more room for them to run.&nbsp;
<h2>BioMarin Stock Holds Firm After Sharp Decline, Bulls Eyeing Comeback</h2>
BioMarin Pharmaceutical Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/bmrn#NASDAQ">BMRN</a>) shares of biotech stock have been effectively range-bound since 2016.
Pharmaceutical companies often experience this, as they depend heavily on positive results from drug and treatment trials rather than more standard fundamental performance for their stock&#39;s direction.&nbsp;
September gave a good example of just how exposed these companies can be, even to updates from their peers in this regard. When positive results from an Ascendis Pharma A/S (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asnd#NASDAQ">ASND</a>) trial were announced, they were seen as a threat to BioMarins&#39; ongoing Voxzogo trials.&nbsp;
BioMarin shares lost more than 20% immediately, but the bears could not take it any lower. They have been consolidating since then, which suggests the bulls could soon be back in control. With BioMarin&#39;s RSI still only at 26, though, while its MACD edges closer to a bullish crossover, this one has all the feel of a comeback rally.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/3-oversold-stocks-with-big-rsi-rebound-potential/">3 Oversold Stocks with Big RSI Rebound Potential</a>&quot; first appeared on MarketBeat.

Mid Cap

Technicals

Markets

Insurance

streetTRACKS Dow Jones U.S. Large Cap Value Index Fund

3 Oversold Stocks with Big RSI Rebound Potential

RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMRN#NASDAQ">BMRN</a>) with a Sector Perform and lowers the price target from $85 to $80.

RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Lowers Price Target to $80

BioMarin Pharmaceutical (BMRN – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Kostas Bilio...

BioMarin Pharmaceutical: Strong Q3 Performance and Promising Growth Outlook

Truist Financial analyst Joon Lee maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report) today. The company's shares closed ye...

BioMarin Pharmaceutical (BMRN) Receives a Buy from Truist Financial

Leerink Partners analyst Joseph Schwartz has reiterated their bullish stance on BMRN stock, giving a Buy rating today. Joseph Schwartz has given hi...

BioMarin Pharmaceutical: Strategic Growth and Shareholder Value Enhancement Drive Buy Rating

Cantor Fitzgerald analyst Olivia Brayer lowered the firm's price target on BioMarin (BMRN) to $90 from $110 and keeps an Overweight rating on the s...

BioMarin price target lowered to $90 from $110 at Cantor Fitzgerald

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Alphabet upgraded, Boeing downgraded: Wall Street's top analyst calls

In a report released today, Jason Zemansky from Bank of America Securities maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Repo...

Bank of America Securities Remains a Buy on BioMarin Pharmaceutical (BMRN)

BioMarin downgraded at William Blair following narrowing of revenue guidance

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on BioMarin Pharmaceutical (BMRN – Research Report), Ne...

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN), Neurocrine (NBIX) and Atricure (ATRC)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

AAPL

AMRN

ANAB

ATRC

BOOT

CARM

EXEL

EYPT

FBLG

GLYC

GOOG

GOOGL

HOTH

INCY

ITCI

IVVD

MEIP

MNKD

NBIX

QRVO

RGLS

RVNC

SPRO

VERI

Press Releases

BioMarin Announces 20% Y/Y Total Revenue Growth in the Second Quarter and Increase in Full-year 2024 Guidance

BioMarin to Host 2024 Investor Day on September 4th in New York

BioMarin Announces New R&D and Business Development Leadership

BioMarin to Present at the 22nd Annual Morgan Stanley Global Healthcare Conference on Thursday, September 5 at 7:45 AM PT / 10:45 AM ET in New York, NY

BioMarin to Host Investor Day Today at 10:30 a.m. Eastern Time

BioMarin Holds Investor Day; Provides New Corporate Strategy and Introduces 2027 Financial Guidance

Junior Biotech Utilizes AI To Shorten Drug Discovery Timelines, Ultimately Saving Lives

BioMarin to Present Data Underscoring Sustained Positive Impact of VOXZOGO® (vosoritide) on Health-Related Quality of Life, Growth and Maintenance of Bone Strength in Children with Achondroplasia at 2024 International Skeletal Dysplasia Society Meeting

Comments

Biomarin Pharmaceutical

Vendite allo scoperto

Biomarin Pharmaceutical (NASDAQ:BMRN) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO